Our Investment in Kheiron Medical: giving people a better fighting chance against cancer
As a child, Peter Kecskemethy spent many hours after school in his mother’s radiology department. He saw first-hand the stress and extreme workloads that she and other radiologists face every day, and the worry when deciding if a patient has cancer or not. He vowed to one day find a way to ease this burden by supporting doctors with more accurate and efficient diagnostic solutions.
Diagnosing and tracking the progression of cancer is an extremely challenging and time-consuming task, even for the most experienced radiologists. A massive shortage of radiologists in many countries, coupled with an ever rising demand for imaging is adding even greater pressure to the doctors who are responsible for making critical decisions about patient care.
That’s why Peter founded Kheiron Medical with his co-founder Tobias Rijken. Kheiron is focused on radically improving imaging-based cancer diagnostics and patient outcomes across the globe to give people a better fighting chance against cancer.
We are proud to announce our partnership with Kheiron Medical. At Atomico, we believe that we are on the cusp of a new age when AI-supported approaches to diagnostics will enable earlier and more accurate detection, tracking, and as a result better treatment outcomes. Kheiron has one of the best machine learning teams in the world and a deep understanding of radiology and the clinical validation required in order to usher in this new era of cancer diagnosis and care. As part of this investment, Atomico Principal Irina Haivas will join the board.
Kheiron’s first product Mia™ (mammography intelligent assessment) is designed to analyze standard Full Field Digital mammography (FFDM) images in a breast cancer screening setting, and to assist radiologists in making a vital clinical decision: to recall a woman for further evaluation or not.
We welcome Kheiron to the Atomico family.